Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NovaBridge Biosciences

Explore full profile

Rockville-based global biotech platform (Nasdaq: NBP, formerly I-Mab) developing givastomig, a CLDN18.2 x 4-1BB bispecific for gastric cancer

Rockville, United StatesFounded 2016Biotech & Life Sciences
Valuation $146M Market cap · 2026
Revenue $3.9M Latest reported FY

About NovaBridge Biosciences

NovaBridge Biosciences (Nasdaq: NBP), formerly I-Mab, is a Rockville, Maryland-based global biotechnology platform company focused on accelerating access to innovative medicines. Founded in 2016 in Shanghai by Dr. Jingwu Zang, the company divested its China operations in 2024, relocated to the US, and changed its name from I-Mab to NovaBridge Biosciences in October 2025, when its ADSs began trading under the ticker NBP. Its lead candidate, givastomig, is a Claudin 18.2 x 4-1BB bispecific antibody co-developed with ABL Bio for HER2-negative, CLDN18.2-positive gastric and gastroesophageal cancer; it entered a global randomized Phase 2 study in February 2026 and received FDA Fast Track designation in June 2026. The pipeline also includes VIS-101, a bifunctional VEGF-A/ANG2 inhibitor held by subsidiary Visara, the PD-L1 x 4-1BB bispecific ragistomig (with ABL Bio), and ex-China rights to the anti-CD73 antibody uliledlimab. CEO is Sean Fu, PhD.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2016
Headquarters
Rockville, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • CBC Group
  • Cambridge Capital
  • Genexine
  • Tasly Pharmaceutical

Series B and later15 investors entered at this stage

  • Hony Capital
  • CDH Investments
  • Hillhouse Capital
  • Ally Bridge Group
  • Tally Capital
  • EDBI
  • HOPU Fund
  • C-Bridge Capital
  • VMS Group
  • I-Mab
  • Bruggemoon
  • Tailong Investment
  • Kaitou Hanrun Capital
  • Qiantang Chengfa
  • Heda Investment

Talent

Book a demo to see the people
Team profiled 20 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China75%
🇺🇸 United States21.3%
🇭🇰 Hong Kong3.8%
3 countries shown
Web traffic by country
130 monthly visits
across markets
🇺🇸 United States76.9%
Top 1 markets shown

Patents

Estimated portfolio value
$57M

57 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NovaBridge Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NovaBridge Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles